The follow-up information is generally not included in these reports, and mortality rates may be underestimated
Pancreatitis history: GLP-1 drugs can affect the pancreas in rare cases
Exclusion criteria comprised a history of previous bariatric surgery, contraindications to IGB insertion or semaglutide use, the presence of gastrointestinal disorders such as inflammatory bowel disease or gastroparesis, severe organ dysfunction (renal, hepatic, or cardiac), pregnancy, and current use of other anti-obesity medications
Pharmacopeia (USP) to ensure the safety and quality of the compounded medication
Early Weeks Most people begin noticing appetite changes within the first few weeks
In their lawsuits, patients say they should have been told about a possible association between Wegovy and an increased risk of developing NAION